Investment analysts at Guggenheim initiated coverage on shares of CRISPR Therapeutics AG Common Shares (NASDAQ:CRSP) in a research report issued on Monday. The firm set a “buy” rating and a $30.00 price target on the stock. Guggenheim’s price target would indicate a potential upside of 65.29% from the company’s previous close.

CRSP has been the subject of several other research reports. Barclays PLC initiated coverage on CRISPR Therapeutics AG Common Shares in a report on Monday. They issued an “overweight” rating and a $22.00 price objective for the company. Piper Jaffray Cos. initiated coverage on CRISPR Therapeutics AG Common Shares in a report on Monday. They issued an “overweight” rating and a $21.00 price objective for the company.

Shares of CRISPR Therapeutics AG Common Shares (NASDAQ:CRSP) opened at 18.15 on Monday. The stock’s market capitalization is $95.51 million. CRISPR Therapeutics AG Common Shares has a 52-week low of $13.75 and a 52-week high of $18.88. The company has a 50-day moving average price of $15.86 and a 200-day moving average price of $15.86.

In related news, Director Simeon George purchased 66,500 shares of the business’s stock in a transaction on Monday, October 24th. The stock was acquired at an average price of $14.00 per share, with a total value of $931,000.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, major shareholder Corp /De/ Celgene purchased 800,150 shares of the business’s stock in a transaction on Monday, October 24th. The shares were bought at an average cost of $14.00 per share, with a total value of $11,202,100.00. The disclosure for this purchase can be found here.

5 Day Chart for NASDAQ:CRSP

Receive News & Stock Ratings for CRISPR Therapeutics AG Common Shares Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CRISPR Therapeutics AG Common Shares and related stocks with our FREE daily email newsletter.